Galatek
AI-driven automation solutions for life sciences laboratories and advanced semiconductor manufacturing.
Website: https://www.galatek.ai/
Cover Block
Publicly reported
| Field | Value |
|---|---|
| Name | Galatek |
| Tagline | AI-driven automation solutions for life sciences laboratories and advanced semiconductor manufacturing. |
| Headquarters | Singapore, Singapore [Crunchbase] |
| Founded | 2025 [Crunchbase] |
| Stage | Series A [PR Newswire, December 2025] |
| Business Model | Hardware + Software |
| Industry | Deeptech |
| Technology | AI / Machine Learning |
| Geography | Southeast Asia |
| Growth Profile | Venture Scale |
| Funding Label | Series A |
| Total Disclosed Funding | Approximately $30,000,000 [PR Newswire, December 2025] |
Links
Publicly reported
Summary and Signal
PUBLIC Galatek is a Singapore-based deep-tech company building AI-driven automation systems for life-sciences laboratories and semiconductor manufacturing, and it merits investor attention because it reported a sizable Series A within its first year and has already tied that financing to manufacturing expansion in Malaysia [PR Newswire, December 2025] [Digital News Asia, June 2026]. The public record is still thin, but the outline is clear enough: Galatek was founded in 2025, positions itself across two precision-heavy end markets, and by December 2025 had announced approximately $30 million in Series A financing to fund product development and broader geographic expansion [PR Newswire, December 2025] [Crunchbase] [AsiaTechDaily, December 2025].
Its core platform on the life-sciences side is Abio, described as a system that combines LIMS, ELN, scientific data management, and robotic automation, while its semiconductor offering includes deep-learning optical inspection, automated overlay measurement, and precision wafer-dicing systems [The AI Insider, December 2025] [AIPressRoom] [Semiconductor Engineering, January 2026]. That cross-stack positioning is the main point of differentiation visible from public sources: the company is not presenting as pure software or pure equipment, but as a hardware-plus-software automation layer for workflows where reproducibility, inspection accuracy, and process control matter [The AI Insider, December 2025] [Semiconductor Engineering, January 2026].
Management visibility is limited, which is material at this stage. Publicly, David Tian, also identified as Zaiwei Tian, is reported as CEO and director, and LinkedIn corroborates him as chief executive, but the available sources do not establish a fuller founding bench or prior operating history for the broader team [Digital News Asia, June 2026] [LinkedIn].
The business model appears to be a mix of hardware and software, which fits the product set and the company’s stated markets, though public disclosures do not yet provide detail on pricing, deployment structure, or customer concentration [PR Newswire, December 2025] [The AI Insider, December 2025]. The next 12 to 18 months likely turn on whether Galatek can convert its early narrative into evidence of repeatable adoption, especially named customers, credible production deployments, and execution against the Penang plant plan, which Digital News Asia said carries a target investment of $100 million [Digital News Asia, June 2026].
One source, partially checked -- This section relies on one independently useful trade publication, one regional business outlet, LinkedIn corroboration for the CEO title, and company-originated funding coverage that is only partially independently confirmed.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Series A |
| Business Model | Hardware + Software |
| Industry / Vertical | Deeptech |
| Technology Type | AI / Machine Learning |
| Geography | Southeast Asia |
| Growth Profile | Venture Scale |
| Funding | Approximately $30,000,000 disclosed Series A [PR Newswire, December 2025] |
Company Overview
PUBLIC
Galatek enters the record with an unusually thin public footprint for a company that disclosed a sizeable Series A soon after formation. Crunchbase lists Galatek as a Singapore-based company founded in 2025, which establishes the basic corporate profile but leaves the founding story, legal entity details, and named founders unfilled in the public materials used for this section [Crunchbase].
The visible chronology is short but still useful. The company appears on Crunchbase as founded in 2025 and headquartered in Singapore, then announced an approximately $30 million Series A in December 2025, according to the same profile [Crunchbase]. On the evidence available here, that is the first confirmed public milestone, and it suggests Galatek moved quickly from formation to institutional fundraising, though the underlying cap table and incorporation particulars are not established in these sources [Crunchbase].
One source, partially checked -- This section relies on a single public company-profile source, Crunchbase, for founding year, headquarters, and funding chronology.
The Product and the Stack
Public record plus analysis
Galatek is making a cross-disciplinary product bet rather than a single-workflow software pitch. Public descriptions position the company at the intersection of laboratory software, robotics, machine vision, and semiconductor tooling, which is notable because those domains usually sit in separate vendor stacks and separate buying motions [The AI Insider, December 2025] [Semiconductor Engineering, January 2026]. The evidence is still relatively thin, and much of it traces back to launch-period coverage, but the basic product shape is consistent across multiple sources.
On the life sciences side, Galatek's Abio platform is described as combining laboratory information management systems, electronic laboratory notebooks, scientific data management, and robotic automation for smart laboratories [The AI Insider, December 2025]. A separate publisher account describes Abio as an integrated system unifying LIMS, ELN, and hardware automation, which broadly corroborates the same architecture even if the underlying feature depth is not yet public [AIPressRoom]. PR-linked coverage also says the company has reported co-creating smart laboratories with the National University of Singapore and forming partnerships with unnamed pharmaceutical firms and research institutions, but those references do not establish named production deployments or module-level functionality beyond the integrated platform claim [PR Newswire, December 2025].
In semiconductors, public descriptions are more equipment-specific. Semiconductor Engineering lists deep-learning optical inspection, automated overlay measurement, and precision wafer-dicing systems among Galatek's products, while later reporting ties the company to a Penang plant focused on scaling manufacturing capacity, with a target investment of US$100 million and Malaysia-origin exports [Semiconductor Engineering, January 2026] [Digital News Asia, June 2026]. One LinkedIn job posting for a field application scientist suggests the company is building some customer-facing technical support around installed systems or evaluations [LinkedIn Job Search, Retrieved 2026]. That is only a directional signal, not proof of installed base scale or a mature service organization.
One source, partially checked -- Supported by named publisher coverage and a public job posting, but product detail remains limited and several claims originate in announcement-based reporting.
The Market They Are Entering
PUBLIC
The market matters now because Galatek is trying to sell into two capex-heavy, precision-sensitive industries, laboratory automation and semiconductor equipment, that tend to reward vendors who can tie software, instrumentation, and workflow control into one system, but the public record here is thinner on market sizing than on product positioning [PR Newswire, December 2025] [The AI Insider, December 2025] [Semiconductor Engineering, January 2026].
The immediate limitation is evidence quality. No named third-party market report with TAM, SAM, or SOM figures appears in the cited materials, so a direct sizing exercise would overstate what is knowable from public sources. What the sources do establish is category exposure: on the life sciences side, Galatek describes Abio as a system that combines laboratory information-management systems, electronic laboratory notebooks, scientific-data management, and robotic automation for smart laboratories [The AI Insider, December 2025] [AIPressRoom]. On the semiconductor side, the company is described as selling deep-learning optical inspection, automated overlay measurement, and precision wafer-dicing systems, which places it adjacent to metrology, inspection, and advanced packaging workflows rather than generic factory software alone [Semiconductor Engineering, January 2026].
That positioning implies demand is tied less to discretionary IT budgets and more to throughput, reproducibility, error reduction, and traceability in regulated or yield-sensitive environments. The life sciences angle benefits when labs want to reduce manual handoffs between record-keeping systems and physical workflows, since Abio is framed as unifying LIMS, ELN, scientific-data management, and automation rather than selling a point tool [The AI Insider, December 2025] [AIPressRoom]. The semiconductor angle benefits when manufacturers continue to spend on inspection accuracy and process control, since the cited offerings sit close to defect detection, overlay measurement, and wafer handling, categories that typically move with process complexity and packaging intensity [Semiconductor Engineering, January 2026].
A second tailwind is geographic manufacturing expansion, although the public evidence supports this only indirectly. Digital News Asia reported that Galatek opened a plant in Penang, Malaysia, with a target investment of US$100 million and Malaysia-origin exports, which suggests management expects enough regional demand, or at minimum enough strategic value in regional production, to justify local manufacturing capacity [Digital News Asia, June 2026]. That does not prove current commercial scale, but it does indicate exposure to Southeast Asia's role in both electronics supply chains and cross-border life sciences manufacturing.
The closest adjacent markets are lab informatics, lab robotics, semiconductor metrology, optical inspection, and precision motion systems. Those are not interchangeable markets, but they are the practical budget pools Galatek appears to be reaching across, because its pitch joins software layers used in scientific record-keeping with automation hardware, and joins computer-vision systems with wafer-processing equipment [The AI Insider, December 2025] [Semiconductor Engineering, January 2026]. The upside in that adjacency is a larger addressable workflow surface; the risk is that buyers in each segment often evaluate vendors against specialist incumbents with narrower, better-defined procurement categories.
Macro and regulatory forces cut in both directions. In laboratories, demand for auditable data handling and standardized workflows can support integrated software-plus-automation stacks, especially where reproducibility and chain of custody matter, though the supplied sources do not name specific compliance frameworks [The AI Insider, December 2025]. In semiconductors, national efforts to add capacity and localize parts of the supply chain can support spending on inspection and production equipment, but those same markets also bring long qualification cycles and customer caution around unproven tooling [Digital News Asia, June 2026] [Semiconductor Engineering, January 2026].
| Cited market proxy | What it indicates for Galatek | Source |
|---|---|---|
| Smart laboratory software plus automation stack | Exposure to lab digitization and workflow automation budgets rather than standalone software only | [The AI Insider, December 2025] |
| Deep-learning optical inspection and overlay measurement | Exposure to semiconductor inspection and metrology spend | [Semiconductor Engineering, January 2026] |
| Precision wafer-dicing systems | Exposure to back-end semiconductor equipment and advanced packaging workflows | [Semiconductor Engineering, January 2026] |
| Penang plant with US$100 million target investment | Regional manufacturing ambition in Southeast Asia, but not a direct demand measure | [Digital News Asia, June 2026] |
The picture that emerges is broad but still mostly categorical. Public evidence supports that Galatek sits at the intersection of several attractive spend areas, but not yet that it has captured a measurable share within any one of them.
One source, partially checked -- This section relies on named public sources for product scope and regional expansion, but no independent third-party market sizing report was available in the cited materials.
The Competitive Field
MIXED Galatek is not competing in a single software lane, it is trying to sell an integrated automation stack across two very different precision markets, which means the relevant alternatives are established lab informatics vendors, lab automation specialists, semiconductor equipment incumbents, and internal engineering teams rather than one clean peer set [The AI Insider, December 2025] [Semiconductor Engineering, January 2026].
The segment map matters because the company’s product claims span both lab workflows and chip-fab tools. On the life-sciences side, the closest alternatives implied by Galatek’s Abio positioning are laboratory information management systems, electronic laboratory notebooks, scientific-data management products, and robotic lab automation that buyers can assemble separately rather than buy as one stack [The AI Insider, December 2025] [AIPressRoom]. On the semiconductor side, the relevant benchmark is different: buyers already purchase optical inspection, overlay measurement, and wafer-dicing from specialist equipment vendors, so Galatek is entering a market where performance, uptime, and process qualification usually matter more than software breadth [Semiconductor Engineering, January 2026].
That leaves Galatek with a potentially interesting edge, but only in narrow form. The public case for differentiation is the claimed combination of lab software, robotic automation, and machine-vision systems under one roof, which could reduce integration work for customers that would otherwise stitch together multiple vendors and internal tooling [The AI Insider, December 2025] [AIPressRoom]. The edge looks perishable rather than durable for now, because the record does not yet show named customers, installed-base scale, proprietary data advantages, or disclosed channel partners that would make replacement difficult once a larger vendor responds [PR Newswire, December 2025] [Digital News Asia, June 2026].
The company is most exposed where buyer requirements become highly specialized. In semiconductors, incumbents in inspection, metrology, and dicing typically benefit from long qualification cycles, service footprints, and customer trust built over years, while Galatek’s public evidence today is a product description plus one funding announcement and a later plant-opening report [Semiconductor Engineering, January 2026] [PR Newswire, December 2025] [Digital News Asia, June 2026]. In life sciences, the risk is different but similar in effect: large labs can continue to buy best-of-breed LIMS, ELN, and automation modules separately, which weakens the sales pitch for an integrated system unless Galatek can show faster deployment or better reproducibility at real sites [The AI Insider, December 2025] [AIPressRoom].
The most plausible 18-month scenario is not category dominance, but proof of fit in a small number of technically demanding accounts. Galatek is the likely winner if customers in Southeast Asia, particularly those near its Penang manufacturing footprint, prefer a newer vendor that can package software and hardware together and support local deployment economics [Digital News Asia, June 2026]. The likely loser if qualification cycles stretch or buyers insist on category-leading point tools is Galatek itself, because no named incumbent is yet public in the source set, while the company still needs to prove that one operating model can win in both smart labs and advanced semiconductor production without losing focus [PR Newswire, December 2025] [Semiconductor Engineering, January 2026].
One source, partially checked -- Based on named-publisher coverage of Galatek's product scope and funding, but no named competitors or independent customer comparisons were confirmed in the public source set.
Opportunity
PUBLIC
If Galatek executes, the prize is not a narrow automation vendor outcome but a chance to become a shared control layer for two expensive, precision-driven environments, life sciences labs and semiconductor production, where software, instrumentation, and workflow errors carry outsized costs [PR Newswire, December 2025] [The AI Insider, December 2025] [Semiconductor Engineering, January 2026].
The headline opportunity rests on an unusual product shape. Galatek is not described as selling only lab software or only semiconductor tools. Public materials instead place it at the intersection of laboratory information systems, electronic notebooks, scientific data management, robotic automation, optical inspection, overlay measurement, and wafer dicing [The AI Insider, December 2025] [AIPressRoom] [Semiconductor Engineering, January 2026]. That matters because buyers in both end markets tend to spend around throughput, reproducibility, and quality control rather than around a single feature. If one company can own the workflow layer that connects data capture, instrument action, and physical automation, it can move from point solution to operating standard. The current evidence is still early and partly company-shaped, but the combination of a disclosed $30 million Series A and a reported Penang plant with a target investment of $100 million suggests Galatek is being built for manufacturing and deployment scale rather than for a software-only experiment [PR Newswire, December 2025] [Digital News Asia, June 2026].
The most credible path to large scale is that Galatek turns a cross-disciplinary stack into a repeatable procurement shortcut. In life sciences, that would mean selling an integrated lab environment rather than separate LIMS, ELN, and automation purchases [The AI Insider, December 2025] [AIPressRoom]. In semiconductors, it would mean attaching AI inspection and motion systems to production-critical metrology and dicing workflows [Semiconductor Engineering, January 2026]. The public record also indicates at least one institutional collaboration, the National University of Singapore, and reported work with unnamed pharmaceutical and semiconductor firms, which is not proof of revenue depth but does suggest the company is already operating in settings where referenceability can matter more than broad brand awareness [PR Newswire, December 2025].
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Smart-lab control plane | Abio becomes the preferred integrated stack for new or redesigned research labs, bundling LIMS, ELN, scientific data management, and robotic automation into one procurement decision | A visible institutional rollout or repeatable lab co-creation model building on the reported National University of Singapore collaboration [PR Newswire, December 2025] | Public sources already describe Abio as an integrated system rather than a standalone software module, which supports a platform sale if early deployments prove easier to implement than stitched-together alternatives [The AI Insider, December 2025] [AIPressRoom] |
| Precision-fab equipment beachhead | The semiconductor line wins a foothold in optical inspection, overlay measurement, or wafer dicing, then expands into adjacent process-control steps | The Penang plant reaches meaningful output and supports Malaysia-origin exports into regional semiconductor supply chains [Digital News Asia, June 2026] | Galatek is already publicly associated with multiple semiconductor product surfaces, and the Penang facility points to an ambition to serve physical production markets rather than remain a design-stage vendor [Semiconductor Engineering, January 2026] [Digital News Asia, June 2026] |
| Cross-vertical automation standard | The same vision AI, motion control, and workflow software stack proves portable enough that wins in one regulated or precision environment lower the cost of selling into the other | A shared architecture across life sciences and semiconductor deployments shows measurable implementation speed or performance consistency across sites [PR Newswire, December 2025] [The AI Insider, December 2025] | The company is already positioned around one automation stack spanning both sectors, which is unusual but strategically valuable if the common technical core is real and reusable [PR Newswire, December 2025] [Semiconductor Engineering, January 2026] |
What compounding could look like is fairly clear, even if the evidence is still early. Each installation can generate three forms of reinforcement: more workflow data inside the software layer, more operating knowledge around how automation behaves in real environments, and more credibility with risk-sensitive buyers that prefer proven integrated systems over custom stitching [The AI Insider, December 2025] [Semiconductor Engineering, January 2026]. In practical terms, a successful smart-lab deployment could improve implementation playbooks for the next lab, while a successful inspection or dicing deployment could sharpen model performance and motion-control tuning for the next fab-facing sale. The reported Penang plant adds a second compounding element, local production capacity and export orientation, which can matter if hardware availability becomes part of the buying decision in Southeast Asia and beyond [Digital News Asia, June 2026].
The size of the win is harder to quantify from public evidence because no validated market-size dataset or clean public comparable is provided in the source set. The more defensible framing is directional. If Galatek were to establish itself as a credible platform vendor across both smart laboratories and semiconductor automation, the company would resemble a high-value infrastructure business that sits above individual instruments and below customer workflows, a position that often supports durable enterprise value because replacement risk is operational rather than cosmetic. With $30 million disclosed at Series A and an early push into manufacturing infrastructure, the upside case is a company worth well into the hundreds of millions or potentially above $1 billion over time (scenario, not a forecast), but that outcome depends on proving repeatable deployments, named reference customers, and commercial adoption beyond announcement-stage evidence [PR Newswire, December 2025] [Digital News Asia, June 2026].
One source, partially checked -- This section relies on one independent trade publication and multiple announcement-based or company-shaped public sources; core product and funding facts are corroborated, but customer depth, market size, and compounding effects remain only partially verified.
Sources
Publicly reported
[Crunchbase] Galatek.ai - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/galatek-ai
[PR Newswire, December 2025] SG-based Startup Galatek Raises $30M Series A to Accelerate AI-powered Automation in Life Sciences and Semiconductor Manufacturing | https://www.prnewswire.com/apac/news-releases/sg-based-startup-galatek-raises-30m-series-a-to-accelerate-ai-powered-automation-in-life-sciences-and-semiconductor-manufacturing-302646550.html
[Digital News Asia, June 2026] MegaRobo-linked Galatek Technologies opens Penang plant with target US$100m investment and Malaysia-origin exports | https://www.digitalnewsasia.com/business/megarobo-linked-galatek-technologies-opens-penang-plant-target-us100m-investment-and
[AsiaTechDaily, December 2025] Singapore-Based Galatek Raises $30M to Scale AI Automation for High-Precision Industries | https://asiatechdaily.com/singapore-based-galatek-raises-30m-to-scale-ai-automation-for-high-precision-industries/
[The AI Insider, December 2025] Galatek Raises $30M Series A to Scale AI Automation Across Life Sciences and Semiconductors | https://theaiinsider.tech/2025/12/24/galatek-raises-30m-series-a-to-scale-ai-automation-across-life-sciences-and-semiconductors/
[AIPressRoom] Galatek Raises $30M for Precision Automation | https://aipressroom.com/galatek-30m-precision-automation/
[Semiconductor Engineering, January 2026] Startup Funding: Q4 2025 | https://semiengineering.com/startup-funding-q4-2025/
[LinkedIn] Glendon Cheok - Fusion Worldwide | LinkedIn | https://www.linkedin.com/in/glendoncheok/
[LinkedIn Job Search, Retrieved 2026] Field Application Scientist (FAS) at Galatek | https://www.linkedin.com/jobs/view/field-application-scientist-fas-at-galatek-4409756846
Articles about Galatek
- Galatek's Abio Platform Combines Vision AI and Robotic Motion for High-Precision Work — The Singapore-based deep-tech company is building its Abio platform for life sciences and semiconductor manufacturing, backed by a new plant in Malaysia.